These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31660373)

  • 21. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
    López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
    Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.
    Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
    Infect Dis Ther; 2021 Sep; 10(3):1227-1252. PubMed ID: 34278551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant
    Gallagher JC; Satlin MJ; Elabor A; Saraiya N; McCreary EK; Molnar E; El-Beyrouty C; Jones BM; Dixit D; Heil EL; Claeys KC; Hiles J; Vyas NM; Bland CM; Suh J; Biason K; McCoy D; King MA; Richards L; Harrington N; Guo Y; Chaudhry S; Lu X; Yu D
    Open Forum Infect Dis; 2018 Nov; 5(11):ofy280. PubMed ID: 30488041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
    Haidar G; Philips NJ; Shields RK; Snyder D; Cheng S; Potoski BA; Doi Y; Hao B; Press EG; Cooper VS; Clancy CJ; Nguyen MH
    Clin Infect Dis; 2017 Jul; 65(1):110-120. PubMed ID: 29017262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.
    Montero MM; Domene-Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer-Alapont L; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Sci Rep; 2021 Nov; 11(1):22178. PubMed ID: 34773066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftolozane/Tazobactam Dosing Requirements Against
    Ruiz J; Ferrada A; Salavert M; Gordon M; Villarreal E; Castellanos-Ortega Á; Ramirez P
    Dose Response; 2020; 18(1):1559325819885790. PubMed ID: 32063809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
    Galani I; Papoutsaki V; Karantani I; Karaiskos I; Galani L; Adamou P; Deliolanis I; Kodonaki A; Papadogeorgaki E; Markopoulou M; Maraki S; Damala M; Prifti E; Vagiakou E; Petinaki E; Fountoulis K; Tsiplakou S; Kirikou H; Souli M; Antoniadou A; Giamarellou H
    J Antimicrob Chemother; 2020 Aug; 75(8):2164-2172. PubMed ID: 32449909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
    Pogue JM; Kaye KS; Veve MP; Patel TS; Gerlach AT; Davis SL; Puzniak LA; File TM; Olson S; Dhar S; Bonomo RA; Perez F
    Clin Infect Dis; 2020 Jul; 71(2):304-310. PubMed ID: 31545346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR)
    Meschiari M; Orlando G; Kaleci S; Bianco V; Sarti M; Venturelli C; Mussini C
    Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
    Díaz-Cañestro M; Periañez L; Mulet X; Martin-Pena ML; Fraile-Ribot PA; Ayestarán I; Colomar A; Nuñez B; Maciá M; Novo A; Torres V; Asensio J; López-Causapé C; Delgado O; Pérez JL; Murillas J; Riera M; Oliver A
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2191-2200. PubMed ID: 30141088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
    Borgatta B; Gattarello S; Mazo CA; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2155-2163. PubMed ID: 28624864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M
    Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.